Role of DPR in Colorectal Cancer

Publication
Video
Special ReportsGastrointestinal Cancers: mCRC (Issue 9)
Volume 1
Issue 9

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response plays an important role in the treatment of colorectal cancer.

Articles in this issue
Phase III Study of Nintedanib Could Provide a New Option for mCRC, According to Expert
Phase III Study of Nintedanib Could Provide a New Option for mCRC, According to Expert
Role of DPR in Colorectal Cancer
Role of DPR in Colorectal Cancer
Overview of the Lume 1 and 2 Trials
Overview of the Lume 1 and 2 Trials
Impact of HER2 Amplification in Colorectal Cancer
Impact of HER2 Amplification in Colorectal Cancer
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancy
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancy
ctDNA Positivity Could Spell Higher Risk of Recurrence in Early-Stage Colon Cancer
ctDNA Positivity Could Spell Higher Risk of Recurrence in Early-Stage Colon Cancer
Novel Immunotherapy Combinations on Horizon for mCRC
Novel Immunotherapy Combinations on Horizon for mCRC
SIRT Added to First-line Chemo Improves Response in Colorectal Cancer
SIRT Added to First-line Chemo Improves Response in Colorectal Cancer
Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
Lenvatinib Is Effective, Regardless of Age in HCC

Lenvatinib Is Effective, Regardless of Age in HCC

April 23rd 2024
Article

No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable hepatocellular carcinoma.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

April Roundtable Roundup: B-cell Lymphoma

April Roundtable Roundup: B-cell Lymphoma

April 22nd 2024
Article

In separate, live virtual events, Kami J. Maddocks, MD, and Sairah Ahmed, MD, discussed the use of loncastuximab tesirine for a patient with later-line diffuse large B-cell lymphoma.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer

Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer

April 20th 2024
Article

During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.

Read More

To Detect More Alterations, Consider Adding Companion Testing to NGS

To Detect More Alterations, Consider Adding Companion Testing to NGS

April 19th 2024
Article

Druggable gene aberrations and predictive biomarkers has allowed for the use of next-generation sequencing technologies to grow.

Read More